Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Lung Cancer

Free Subscription 24.11.2025 1 Am J Clin Oncol 1 Am J Clin Pathol 1 Ann Surg Oncol 3 Ann Thorac Surg 6 BMC Cancer 1 Cancer 1 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Lett 1 Cancer Res 1 Carcinogenesis 1 Chest 3 Clin Cancer Res 5 Clin Lung Cancer 4 Clin Nucl Med 2 Eur J Cardiothorac Surg 2 Int J Radiat Oncol Biol Phys 1 J Thorac Cardiovasc Surg 3 J Thorac Oncol 1 JAMA Oncol 11 Lung Cancer 2 N Engl J Med 1 Nat Med 2 Oncol Rep 1 Oncologist 2 PLoS One 1 Proc Natl Acad Sci U S A 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. YANG D, Cui BH, Wang HY, Zhang ZR, et al
   Prognostic Value of Multiparameter Biomarkers in Pleural Effusion of Patients With Non-small Cell Lung Cancer for Predicting Survival Outcomes: A Prospective Cohort Study.
   Am J Clin Oncol. 2025 Nov 19. doi: 10.1097/COC.0000000000001269.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

2. MAJOR CK, Cocelli CJ, Khrizman P, Shersher DD, et al
   Implementation of a next-generation sequencing and PD-L1 immunohistochemistry reflex testing protocol for non-small cell lung cancers improves turnaround time.
   Am J Clin Pathol. 2025;164:813-819.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. KHAN AA, Naeem W, Ansari M, Adebayo OW, et al
   ASO Visual Abstract: Skeletal Muscle Gauge as a Prognosticator of Survival in Resected Early-Stage Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Nov 21. doi: 10.1245/s10434-025-18786.
   PubMed        
   
   

   
   Ann Thorac Surg

4. NOMURA K, Watanabe T, Takamori S, Hamada A, et al
   Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus).
   Ann Thorac Surg. 2025 Oct 30:S0003-4975(25)01059.
   PubMed         Abstract available
   
   
5. WILDER FG, Bostock IC, Watkins A, Erfe JM, et al
   Social Determinants of Health in Thoracic Surgery: Critical Points for Understanding and Implementing Change.
   Ann Thorac Surg. 2025;120:1188-1194.
   PubMed         Abstract available
   
   
6. ORTIZ BA, Engrav SK, Roden AC, Boland JM, et al
   Impact of frozen section pathology examination of surgical margins in sublobar pulmonary resections for clinical stage IA NSCLC.
   Ann Thorac Surg. 2025 Apr 25:S0003-4975(25)00338.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. ZHANG Y, Li W, Zhang W, Xing S, et al
   Low-dose radiotherapy combined with chemoimmunotherapy yields superior survival outcomes compared with chemoimmunotherapy alone for patients with small cell lung cancer with liver metastasis: a retrospective study.
   BMC Cancer. 2025;25:1785.
   PubMed         Abstract available
   
   
8. NING G, Sihan C, Daihong J, Zhilong Z, et al
   Effect of position management combined with active cycle of breathing techniques on reducing postoperative pulmonary complications in lung cancer patients.
   BMC Cancer. 2025;25:1780.
   PubMed         Abstract available
   
   
9. PARK SE, Hwang IG, Choi JH
   Skeletal muscle loss and associated clinical outcomes in patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
   BMC Cancer. 2025;25:1772.
   PubMed         Abstract available
   
   
10. BAI M, Li J
    Lung cancer and COVID-19 susceptibility and severity: a Mendelian randomization analysis.
    BMC Cancer. 2025;25:1771.
    PubMed         Abstract available
    
    
11. MEI T, Wang T, Zhou Q
    Assessing first-line treatment for advanced EGFR-mutated NSCLC in diverse clinicopathological subgroups: a systematic review and network meta-analysis.
    BMC Cancer. 2025;25:1767.
    PubMed         Abstract available
    
    
12. SU T, Li L, Jing C, Chen L, et al
    KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis.
    BMC Cancer. 2025;25:1794.
    PubMed         Abstract available
    
    

    
    Cancer

13. OLSON JMG, Knight JR, Copeland AM, Mei LS, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Strengthening connections between state-based initiatives.
    Cancer. 2025;131:e70143.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

14. ZHOU Y, Huang W, Hang X, He Y, et al
    Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences.
    Cancer Chemother Pharmacol. 2025;95:106.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

15. HENDERSON LM, Lund JL, Durham DD, Baggett CD, et al
    Burden and impact of frailty and comorbidity in individuals screened for lung cancer.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Lett

16. LIU Y, Prasad CB, Qiu Z, Singh D, et al
    CD40 drives tumor growth in non-small cell lung cancer via non-canonical immune-independent mechanisms.
    Cancer Lett. 2025;637:218151.
    PubMed        
    
    

    
    Cancer Res

17. REINECKE JB, Jimenez Garcia L, Saraf AJ, Hinckley J, et al
    Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic Niche.
    Cancer Res. 2025;85:4341-4358.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

18. LIU W, Liu Y, Xie Y, Huang H, et al
    HS-10296 (almonertinib) enhances radiosensitivity in EGFR-mutant nonsmall cell lung cancer (including T790M) through inhibition of EGFR downstream signaling and DNA damage repair.
    Carcinogenesis. 2025;46:bgaf070.
    PubMed         Abstract available
    
    

    
    Chest

19. SAKOWITZ S, Tupper HI, Benjamin LN, Oh S, et al
    Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer.
    Chest. 2025 Nov 12:S0012-3692(25)05681-8. doi: 10.1016/j.chest.2025.
    PubMed        
    
    

    
    Clin Cancer Res

20. YANG Y, Nilsson MB, Yu X, Poteete A, et al
    The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells.
    Clin Cancer Res. 2025;31:4745-4762.
    PubMed         Abstract available
    
    
21. PECCI F, Li H, Di Federico A, Wu J, et al
    First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy +/- Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
    Clin Cancer Res. 2025;31:4802-4813.
    PubMed         Abstract available
    
    
22. BALASUBRAMANIAN A, Marceaux C, Kanwal S, Tarasova I, et al
    Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.
    Clin Cancer Res. 2025;31:4644-4654.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

23. MAI WX, Frick MA, Jackson S, Richter SA, et al
    Association Between Inter-Fraction Volume Changes and Patient Outcomes from Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Clin Lung Cancer. 2025 Oct 25:S1525-7304(25)00281.
    PubMed         Abstract available
    
    
24. PAIK PK, Zhang J, West HJ, Riess JW, et al
    Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options.
    Clin Lung Cancer. 2025 Oct 6:S1525-7304(25)00241.
    PubMed         Abstract available
    
    
25. CHOUCAIR K, Jang H, Jalal SI, Hadid T, et al
    Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer a Systemic Review and Meta-analysis.
    Clin Lung Cancer. 2025;27:1-12.
    PubMed         Abstract available
    
    
26. CATLI MM, Onder AH
    Re: "Re-biopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer with EGFR/ALK/ROS Oncogenic Driver Progression after Optimal Targeted Therapy: A Multicenter Real-World Analysis".
    Clin Lung Cancer. 2025;27:13-14.
    PubMed        
    
    
27. AGRAWAL A, Chitikela SD, Rastogi A, Khurana S, et al
    Germline Variants in Indian Non-Small Cell Lung Cancer Patients With Familial Aggregation: A Prospective Cohort Study.
    Clin Lung Cancer. 2025;27:15-23.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

28. DELEU AL, Berghmans T, Flamen P, Brandao M, et al
    Secondary Pulmonary Hypertrophic Osteoarthropathy Detected on [68Ga]Ga-FAPI-46 PET/CT.
    Clin Nucl Med. 2025 Mar 24. doi: 10.1097/RLU.0000000000005859.
    PubMed         Abstract available
    
    
29. LIU H, Gong W, Ji Y, Xu T, et al
    68Ga-FAP-2286 PET/CT Imaging of Nuclear Protein of the Testis Midline Carcinoma in the Lung.
    Clin Nucl Med. 2025 Jun 6. doi: 10.1097/RLU.0000000000006020.
    PubMed         Abstract available
    
    
30. FILIPPI L, Picchi E, Danieli R, Lacanfora A, et al
    Perineural Involvement and Lung Metastasis From Hormone-Sensitive Prostate Cancer: Multimodal Imaging With MRI and Dual-tracer PSMA/[18F]FDG PET/CT.
    Clin Nucl Med. 2025 Jul 7. doi: 10.1097/RLU.0000000000005854.
    PubMed         Abstract available
    
    
31. ZHAO Y, Zhou W, Bai X
    18F-FDG PET/CT and 68Ga-DOTATATE PET/CT Findings of Metastatic Lung Inflammatory Myofibroblastic Tumor.
    Clin Nucl Med. 2025;50:1203-1205.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

32. LEE JO, Ahn Y, Yun JK, Lee SM, et al
    Quantitative Analysis of Changes in the Thoracic Anatomy over Time after Pneumonectomy Using Computed Tomography.
    Eur J Cardiothorac Surg. 2025;67:ezaf364.
    PubMed         Abstract available
    
    
33. NISHIDA T, Yanagawa M, Sato J, Nishigaki D, et al
    Artificial Intelligence-Advanced Imaging for Solid-Type Lung Adenocarcinoma: Towards Greater Clinical Relevance.
    Eur J Cardiothorac Surg. 2025;67:ezaf385.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

34. AVERBUCH I, Appel S, Blumenfeld P, Goltser A, et al
    Assessment of the Effective Dose to Immune Cells as an Independent predictor of Durvalumab response in Non-Small Cell Lung Cancer patients after Chemoradiotherapy: A Multi-Center Study.
    Int J Radiat Oncol Biol Phys. 2025 Nov 14:S0360-3016(25)06478.
    PubMed         Abstract available
    
    
35. THOMPSON LL, Amin PM, Shah S, Lipson SM, et al
    Associations Between G8 Geriatric Screening Score, Charlson Comorbidity Index, AI-Based Age Phenotype, and Overall Survival in Older Adults With Stage I-II Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2025;123:1295-1305.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

36. WOODSON DRP, Kapula N, Liou DZ, Elliott IA, et al
    The Association of Short-Term Outcomes and Long-Term Survival After Lung Cancer Resection.
    J Thorac Cardiovasc Surg. 2025 Nov 17:S0022-5223(25)00979.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

37. ROSS JS, Thummalapalli R, Febres-Aldana CA, Muldoon D, et al
    Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2025 Nov 17:S1556-0864(25)02904.
    PubMed         Abstract available
    
    
38. YANG JJ, Mu Y, Wang ZH, Duan JC, et al
    Andamertinib in Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results from the Phase 2 KANNON Study.
    J Thorac Oncol. 2025 Nov 15:S1556-0864(25)02902.
    PubMed         Abstract available
    
    
39. ZHU H, Al Saifi S, Bahig H, Cooper A, et al
    Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subc
    J Thorac Oncol. 2025 Nov 14:S1556-0864(25)02899.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

40. YANG JT, Yerramilli D, Pentsova E, Wolden S, et al
    Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial.
    JAMA Oncol. 2025;11:1293-1301.
    PubMed         Abstract available
    
    

    
    Lung Cancer

41. ONDER AH
    Letter to the Editor: On the clinical irrelevance of SUCRA rankings in relapsed small-cell lung cancer.
    Lung Cancer. 2025;210:108837.
    PubMed        
    
    
42. PAN H, Yin H, Li W, Kong W, et al
    Threshold of adequate resection margin for sub-lobar resection in peripheral clinical stage IA1-2 non-small cell lung cancer with tumor spread through air spaces.
    Lung Cancer. 2025;210:108838.
    PubMed         Abstract available
    
    
43. KHORASANCHI A, Li M, Zhao S, Wei L, et al
    Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy.
    Lung Cancer. 2025;210:108832.
    PubMed         Abstract available
    
    
44. CAI H, Shu XO, Wu S, Gao YT, et al
    Higher lung cancer risk among female never-smokers than males in a large married couple study.
    Lung Cancer. 2025;210:108836.
    PubMed         Abstract available
    
    
45. MA L, Zhang X, Xu S, Dai J, et al
    NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancer.
    Lung Cancer. 2025;210:108841.
    PubMed         Abstract available
    
    
46. LUO B, Liang S, Zhong L, Gao W, et al
    Impact of N1 lymph node burden on survival outcomes in non-skip pN2 non-small-cell lung cancer.
    Lung Cancer. 2025;210:108839.
    PubMed         Abstract available
    
    
47. NICOS M, Galant N, Kowalczyk A, Peksa R, et al
    Genetic composition and evolutionary trajectories of brain metastasis in non-small-cell lung cancer.
    Lung Cancer. 2025;210:108842.
    PubMed         Abstract available
    
    
48. STEWART DJ, Zhang B, Kurzrock R
    Tarlatamab population survival kinetics in extensive-stage small cell lung cancer: brief report.
    Lung Cancer. 2025;210:108844.
    PubMed         Abstract available
    
    
49. KAKUTO S, Uchibori K, Yamamoto Y, Miyauchi E, et al
    Tumor heterogeneity involving SCLC with a single exon deletion in RB1 and adenocarcinoma with EGFR-L718V mutation in EGFR-TKI-resistant lung cancer.
    Lung Cancer. 2025;210:108833.
    PubMed         Abstract available
    
    
50. BATAH H, Zabor EC, Adcock B, Lee M, et al
    Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study.
    Lung Cancer. 2025;210:108847.
    PubMed         Abstract available
    
    
51. TORCHIA A, Sabatini A, Bengala E, Di Civita MA, et al
    First-line treatment in EGFR-mutated non-small cell lung cancer: brief report of an individual patient data comparison of phase 3 clinical trials.
    Lung Cancer. 2025;210:108845.
    PubMed         Abstract available
    
    

    
    N Engl J Med

52. LI X, Mu X
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2025;393:2068-2069.
    PubMed        
    
    
53. FORDE PM, Provencio M, Girard N
    Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.
    N Engl J Med. 2025;393:2069-2070.
    PubMed        
    
    

    
    Nat Med

54. LOVLY CM, McDonald NT, Chen H, Ortiz-Cuaran S, et al
    Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.
    Nat Med. 2025 Nov 20. doi: 10.1038/s41591-025-04116.
    PubMed        
    
    

    
    Oncol Rep

55. YIN Y, Tang L, Shi L
    [Corrigendum] Src homology phosphotyrosyl phosphatase 2 mediates cisplatin?related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
    Oncol Rep. 2026;55:21.
    PubMed         Abstract available
    
    
56. WANG K, Li Y, Guo Z, Song L, et al
    Role of the SOX family in non?small cell lung cancer: Molecular mechanisms and therapeutic implications (Review).
    Oncol Rep. 2026;55:19.
    PubMed         Abstract available
    
    

    
    Oncologist

57. CHEN KT, Sethunath V, Ebot E, Decker B, et al
    Coverage of Actionable Alterations In Non-Small Cell Lung Cancer by Hybrid Capture-Based FoundationOne(R)CDx Compared With Amplicon-based Oncomine DX.
    Oncologist. 2025 Nov 20:oyaf390. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    PLoS One

58. YU L, Yu X, Ma C, Zhang X, et al
    Safety and efficacy of radiotherapy combined with immunotherapy in limited-stage small cell lung cancer a single-arm meta-analysis and systematic review.
    PLoS One. 2025;20:e0337459.
    PubMed         Abstract available
    
    
59. CHENG M, Zhang J, Jin L, Yu C, et al
    Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series.
    PLoS One. 2025;20:e0337237.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

60. KLOSOWSKI ML, Cronise KE, Palmer EP, McAuliffe K, et al
    Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance.
    Proc Natl Acad Sci U S A. 2025;122:e2423894122.
    PubMed         Abstract available
    
    

    
    Thorax

61. DELVA F, Gramond C, Thaon I, Lacourt A, et al
    Coexposure to asbestos, mineral wool, crystalline silica and refractory ceramic fibres and risk of lung cancer and mesothelioma.
    Thorax. 2025 Nov 20:thorax-2024-222020. doi: 10.1136/thorax-2024-222020.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.